Tim M. Mayleben
2013 - Esperion Therapeutics
In 2013, Tim M. Mayleben earned a total compensation of $3.5M as President and Chief Executive Officer at Esperion Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $160,000 |
|---|---|
| Option Awards | $2,890,165 |
| Salary | $400,000 |
| Total | $3,450,165 |
Mayleben received $2.9M in option awards, accounting for 84% of the total pay in 2013.
Mayleben also received $160K in non-equity incentive plan and $400K in salary.
Rankings
In 2013, Tim M. Mayleben's compensation ranked 2,139th out of 12,286 executives tracked by ExecPay. In other words, Mayleben earned more than 82.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,139 out of 12,286 | 83rd |
Division Manufacturing | 700 out of 4,612 | 85th |
Major group Chemicals And Allied Products | 194 out of 1,462 | 87th |
Industry group Drugs | 130 out of 1,156 | 89th |
Industry Pharmaceutical Preparations | 110 out of 890 | 88th |
Source: SEC filing on April 28, 2016.
Mayleben's colleagues
We found one more compensation record of an executive who worked with Tim M. Mayleben at Esperion Therapeutics in 2013.
2013
Roger Newton
Esperion Therapeutics
Chief Scientific Officer
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019